**Table 1: Summary of Included Studies**

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study, Year** | **Country** | **Study Design** | **Setting** | **Intervention Type** | **Follow-up Time** | **Intervention Screened/Total (%)** | **Control Screened/Total (%)** | **Change in screening (%)** |
| Singal et al,32 2016 | USA | RCT | Safety-Net | Mailed FIT | 12 months | 1410/2400  (58.8) | 355/1199  (29.6) | 29.1 |
| Goldman et al,28 2015 | USA | RCT | FQHC | Mailed FIT | 6 months | 77/210  (36.7) | 31/210  (14.8) | 21.9 |
| Baker et al,26 2014 | USA | RCT | FQHC | Mailed FIT | 6 months | 185/225  (82.2) | 84/225  (37.3) | 44.9 |
| Hendren et al,30 2014 | USA | RCT | Safety-Net | Mailed FIT | 12 months | 43/114  (37.8) | 21/126  (16.7) | 21.1 |
| Charlton et al,27 2014 | USA | RCT | VA | Mailed FIT | 6 months | 71/500  (14.2) | 0/500  (0) | 14.2 |
| Gupta et al,29 2013 | USA | RCT | Safety-Net | Mailed FIT | 12 months | 648/1593  (40.7) | 471/3898  (12.1) | 28.6 |
| Levy et al,31 2013 | USA | RCT | PCCs | Mailed FIT | 15 months | 105/186  (56.4) | 33/185  (17.8) | 38.6 |
| Giorgi Rossi et al,23 2011 | Italy | RCT | National | Mailed FIT | 3 months | 1006/1569 (64.1) | 908/1600  (56.8) | 7.4 |
| Giorgi Rossi et al,23 2011 | Italy | RCT | National | Mailed FIT | 3 months | 307/2107  (14.6) | 226/ 2112 (10.7) | 3.9 |
| Myers et al,21 2007 | USA | RCT | Safety-Net | Mailed FIT | 24 months | 177/387  (45.7) | 126/387  (32.6) | 13.2 |
| Senore et al,34 2015 | Italy | RCT | National | Pre-FIT Reminder | 9 months | 3888/10257 (37.9) | 3580/10444 (34.3) | 3.6 |
| Kempe et al,33 2012 | USA | Quasi-Exp | KPCO | Pre-FIT Reminder | 12 months | 3497/8583  (40.7) | 14952/41232  (36.3) | 4.5 |
| Van Roon et al,35 2011 | Netherlands | RCT | National | Pre-FIT Reminder | N/A | 1539/2390  (64.4) | 1462/2394  (61.1) | 3.3 |
| Cole et al,22 2007 | Australia | RCT | CHC | Pre-FIT Reminder | 3 months | 290/600  (48.3) | 237/600  (39.5) | 8.8 |
| Levy BT et al,36 2012 | USA | RCT | PCCs | Post-FIT Reminder | 15 months | 91/187  (48.7) | 84/186  (45.2) | 3.5 |
| Meyers et al,21 2007 | USA | RCT | Safety-Net | Post-FIT Reminder | 24 months | 187/386  (48.4) | 177/387  (45.7) | 2.7 |
| Myers et al,21 2007 | USA | RCT | Safety-Net | Tailored Messaging | 24 months | 168/386  (43.5) | 177/387  (45.7) | -2.2 |
| Cole et al,22 2007 | Australia | RCT | CHC | Tailored Messaging | 3 months | 242/600  (40.3) | 237/600  (39.5) | 0.8 |
| Cole et al,22 2007 | Australia | RCT | CHC | Tailored Messaging | 3 months | 216/600  (36.0) | 237/600  (39.5) | -3.5 |
| Davis et al,37 2016 | USA | RCT | FQHC & CHC | Small Media | 6 months | 164/210  (78.1) | 172/206  (90.3) | -5.4 |
| Gupta et al,38 2016 | USA | RCT | Safety-Net | Financial Incentives | 12 months | 738/2000  (36.9) | 2379/6565  (36.2) | 0.7 |
| Potter et al,39 2013 | USA | RCT | KPNC | FIT w/ vaccination | 3 months | 900/3351  (26.9) | 336/2884  (11.7) | 15.2 |
| Potter et al,40 2011 | USA | Obs. | KPNC | FIT w/ vaccination | 3 months | 853/2812  (30.3) | 635/4653  (13.7) | 16.6 |
| Rat et al,25 2017 | France | Cluster RCT | National | Provider Alerts | 12 months | 123/496\*  (24.8) | 94/455\*  (20.6) | 4.2 |
| Guiriguet et al,24 2016 | Spain | Cluster RCT | National | Provider Alerts | 12 months | 9536/21619  (44.1) | 8196/19423  (42.2) | 1.9 |

Abbreviations: RCT (Randomized Controlled Trial); FQHC (Federally Qualified Heath Center); VA (Veterans Administration Hospital); PCCs (Primary Care Clinics); KPCO (Kaiser Permanente Colorado); CHC (Community Health Centers); KPNC (Kaiser Permanente Northern California); Obs. (Observational Study)

\*Authors did not provide numbers of patients in intervention and control arms but did provide percentage screened.

**Table 2: Detailed Characteristics of Included Studies**

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study, Year** |  |  |  |  |  |  | **Informed Consent Waiver** | **Prior screening rate (%)** | **Type of FIT** | **FIT follow-up rate (%)** |
|  | **Mean age**  **(Years)** | **Women**  **(%)** | **NHC**  **(%)** | **AA**  **(%)** | **Hispanic**  **(%)** | **English speakers (%)** |  |  |  |  |
| Singal,32 2016 | 56.1 | 61.6 | 21.5 | 24.1 | 48.5 | 61.3 | Yes | N/A | Polymedco OC-Auto FIT CHEK | 49.3 |
| Goldman,28 2015 | 57.3 | 66.0 | 15.7 | 16.4 | 62.1 | 51.5 | Yes | 0 | Polymedco OC-Light | 30.0 |
| Baker,26 2014 | 59.5 | 71.6 | N/A | N/A | 89.3 | N/A | Yes | 100 | Polymedco OC-Light | 58.6 |
| Hendren,30 2014 | 53.9 | N/A | 53.3 | 39.6 | N/A | N/A | Yes | N/A | N/A | N/A |
| Charlton,27 2014 | 59.3 | 0.1 | N/A | N/A | N/A | N/A | No | N/A | N/A | 81.2 |
| Gupta,29 2013 | 59.0 | 63.9 | 41.0 | 23.3 | 28.9 | 83.3 | Yes | N/A | Polymedco OC-Auto FIT CHEK | 81.7 |
| Levy,31 2013 | N/A | 52.8 | 98.1 | 0.01 | N/A | N/A | No | N/A | Clearview Ultra FIT | N/A |
| Giorgi Rossi,23 2011 | N/A | N/A | N/A | N/A | N/A | N/A | No | 100 | OC-Hemodia | N/A |
| Giorgi Rossi,23 2011 | N/A | N/A | N/A | N/A | N/A | N/A | No | Previously unresponsivea | OC-Hemodia | N/A |
| Myers,21 2007b | N/A | N/A | N/A | N/A | N/A | N/A | No | N/A | InSure FIT | N/A |
| Senore,34 2015 | N/A | 53.1 | N/A | N/A | N/A | N/A | Yes | N/A | N/A | N/A |
| Kempe,33 2012b | N/A | N/A | N/A | N/A | N/A | N/A | Yes | N/A | OC-Sensor Micro | 79.0 |
| Van Roon,35 2011 | 60.3 | 51.0 | N/A | N/A | N/A | N/A | No | N/A | OC-Sensor Micro | N/A |
| Cole,22 2007 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | InSure FIT | N/A |
| Levy BT,36 2012 | 61.2 | 51.7 | 99.2 | 0.5 | N/A | N/A | No | N/A | Clearview Ultra FIT | N/A |
| Meyers,21 2007b | N/A | N/A | N/A | N/A | N/A | N/A | No | N/A | InSure FIT | N/A |
| Myers,21 2007b | N/A | N/A | N/A | N/A | N/A | N/A | No | N/A | InSure FIT | N/A |
| Cole,22 2007 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Insure FIT | N/A |
| Cole,22 2007 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Insure FIT | N/A |
| Davis,37 2016 | 55.7 | 53.6 | 66 | 28.2 | N/A | N/A | No | 32.0 | N/A | 76.2 |
| Gupta,38 2016 | 56.0 | 61.8 | 37.1 | 24.4 | 29.2 | 83.3 | Yes | N/A | Polymedco OC-Sensor | 57.0-63.0 |
| Potter,39 2013 | 61.5 | 57.4 | 46.6 | 5.7 | N/A | 87.5 | Yes | N/A | Polymedco OC-Auto FIT CHEK | N/A |
| Potter,40 2011 | 63.1 | 55.4 | 51.0 | 1.7 | 11.3 | 88.0 | Yes | N/A | Polymedco OC-Micron | N/A |
| Rat,25 2017 | 60.9 | 38.9 | N/A | N/A | N/A | N/A | Yes | Previously unresponsivea | N/A | N/A |
| Guiriguet,24 2016 | 58.7 | 53.6 | N/A | N/A | N/A | N/A | Yes | 0 | N/A | N/A |

Abbreviations: N/A- not available

a- Authors stated that participants had been previously unresponsive but did not specify proportion that had never completed screening.

b- Demographics published on the sub-groups combined but was not available by study sub-groups.

**Table 3: Quality Assessment for Randomized Controlled Trials or Controlled Trialsa**

| **Author, Year** |  |  | ***Cochrane Collaboration’s tool for assessing risk of bias (ROB)*** | | | | | | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | ***Selection Bias*** | | ***Performance Bias*** | ***Detection Bias*** | ***Attrition Bias*** | ***Reporting Bias*** | ***Other Bias*** |  |
| **Study Design** | **Random sequence generation** | **Allocation concealment** | **Blinding of participants** | **Blinding of outcome assessment** | **Incomplete outcome data** | **Selective reporting** | **Other sources of bias** | **Summary assessment High/Low/**  **Unclear ROB** |
| Singal,32 2016 | RCET | Yes | Yes | Yes | Yes | No | No | No | Low |
| Goldman,28 2015 | RCT | Yes | Yes | Unclear | Yes | No | No | Unclear | Low |
| Baker,26 2014 | RCT | Yes | Yes | Unclear | Yes | No | No | No | Low |
| Hendren,30 2014 | RCT | Yes | Yes | Unclear | Yes | Unclear (outcomes reported values vary from patients randomized). | No | Unclear | Unclear |
| Charlton,27 2014 | RCT | Yes | Unclear | Unclear | Yes | No | No | Potential for volunteer bias | High |
| Gupta,29 2013 | RCET | Yes | Yes | Yes | Yes | Yes (small and similar across study arms) | No | No | Low |
| Levy,31 2013 | RCT | Yes | Unclear | Unclear | Yes | Unclear | No | Unclear, overall low participation | Unclear |
| Giorgi Rossi,23 2011 | RCT | Yes | Unclear | Unclear | Unclear | No | No | No | Unclear |
| Myers,21 2007 | RCT | Unclear | No | Unclear | Study research assistants performed  an endpoint chart audit at 24 months after randomi-  zation.  Study research assistants performed  an endpoint chart audit at 24 months after randomi-  zation.  Study research assistants performed  an endpoint chart audit at 24 months after randomi-  zation.  Yes | Unclear | No | No | Unclear |
| Senore34, 2015 | RCT | Yes | Yes | Unclear | Unclear | Yes (one site completed 2/3 study arms) | Unclear (outcomes not explicitly stated) | No | High |
| Kempe,33 2012 | Quasi-Experimental | No | Unclear | Unclear | Unclear | No | No | No | Unclear |
| Van Roon,35 2011 | RCT | Yes | Unclear | Unclear | Unclear | Yes (not intention-to-treat analysis) | No | No | High |
| Cole,22 2007 | RCT | Unclear | Unclear | Unclear | Unclear | No | No | Unclear | Unclear |
| Levy,36 2012 | RCT | Unclear | Unclear | Unclear | Unclear | No | No | Unclear | Unclear |
| Davis,37 2016 | RCT | Unclear | Unclear | Unclear | Unclear | No | No | Potential for volunteer bias | High |
| Gupta,38 2016 | RCET | Yes | Unclear | Unclear | Unclear | No | No | No | Unclear |
| Potter,39 2013 | RCT | Yes | Unclear | Unclear | Unclear | No | No | Unclear, overall low participation | Unclear |
| Rat,25 2017 | Cluster RCT | Yes | Unclear | Unclear | Yes | No | No | No | Low |
| Guiriguet,24 2016 | Cluster RCT | Yes | Yes | Yes | Yes | No | No | No | Low |

Abbreviations: RCET- Randomized Comparative Effectiveness Trial; RCT- Randomized Control Trial

a- Studies assessed using the Cochrane criteria for assessing risk of bias 19. One study excluded because they did not use a RCT or CT design 40.